Research digest / dosing in the trials
Tesamorelin Dosing as Studied in the Trials
The regimens used in the published randomized trials, the route, the storage and pharmacokinetic constraints, and why dosing was once daily — described as research context, never as guidance.
The short version
In the trials, tesamorelin was given as a 2 mg injection under the skin once a day — that was the dose in both major Phase 3 studies and the FDA-approved regimen for the HIV use. The drug clears the blood fast (within about half an hour), but its downstream effect on IGF-1 (a growth signal) lasts through the day, which is why once daily worked. This page describes what was studied. It is not a dosing instruction, and the research-grade material discussed here is for laboratory study, not for people to inject.
Dosing in the trials
The extensively studied tesamorelin regimen is 2 mg subcutaneously once daily. That was the dose in both pivotal Phase 3 trials in HIV-associated lipodystrophy and the FDA-approved regimen [1][2][5]. A lower 1 mg/day arm has appeared in secondary studies, but the 2 mg once-daily paradigm is the one the visceral-fat efficacy data rest on.
Later reformulations changed the concentration and presentation rather than the underlying once-daily logic; across the program, the extensively validated paradigm remains 2 mg once daily by subcutaneous injection. These are doses administered to a specific HIV-positive clinical-trial population under medical supervision — described here as research context, not as a recommendation. No human dosing instruction is given on this site, and the material discussed is research-grade tesamorelin supplied for laboratory use, not the approved finished drug.
Route and administration as studied
Subcutaneous injection — specifically at an abdominal site in the trials — is the only route studied in clinical trials and the only FDA-approved route [5]. There is no oral, intranasal, or transdermal tesamorelin in the trial record; the peptide would not survive gastrointestinal digestion intact, which is why every studied regimen used subcutaneous delivery.
Tesamorelin is supplied as a lyophilized (freeze-dried) powder requiring reconstitution before use. The FDA prescribing information specifies refrigerated storage and use of the reconstituted solution within a defined window — constraints that reflect the peptide's physical instability once in solution [5].
Half-life and the once-daily rationale
Tesamorelin clears the plasma quickly. Population PK modeling reported an apparent clearance around 1,060 L/h, and secondary sources describe a terminal half-life on the order of 26-38 minutes [11]. On its face, that brevity would argue against once-daily dosing.
The resolution is the IGF-1 effect. Although the peptide itself is gone from the plasma within roughly half an hour, the IGF-1 elevation it triggers persists across the dosing interval, which is the pharmacodynamic basis for once-daily administration [11]. The trans-3-hexenoyl N-terminal modification is what makes even the brief plasma window possible, by blocking the DPP-IV cleavage that inactivates native GHRH almost immediately [6]. The full account is on the mechanism page.
Why the dose does not generalize
The 2 mg once-daily regimen was validated in HIV patients with lipodystrophy — the only population with pivotal efficacy data [1][2]. There is no completed large randomized trial establishing a dose for general-population fat loss, anti-aging, or any non-HIV use, all of which are off-label [5].
Visceral fat also reaccumulated after discontinuation in the 52-week program, so the studied effect depended on continued dosing rather than a fixed course [2]. Anyone reading the dosing literature should treat the 2 mg figure as a documented trial parameter in a specific population, not a generalizable protocol — and the research-grade material discussed here is not for human use. For the side effects and safety record, see the research page.